Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

• ClinicalTrials.gov Identifier: NCT03939689
• Recruitment Status: Active, not recruiting
• First Posted: May 7, 2019
• Last Update Posted: August 4, 2022
• Sponsor: Progenics Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Progenics Pharmaceuticals, Inc.

Tracking Information

• First Submitted Date: May 3, 2019
• First Posted Date: May 7, 2019
• Last Update Posted Date: August 4, 2022
• Actual Study Start Date: May 30, 2019
• Estimated Primary Completion Date: June 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 24, 2021)

PSA Response Rate [ Time Frame: Up to 53 weeks ]

The proportion of participants with a PSA response according to PCWG3 criteria defined as the first occurrence of a 50 percent or more decline in PSA from baseline, confirmed by a second measurement at least 3 weeks later.

Original Primary Outcome Measures (submitted: May 6, 2019)

PSA response rate [ Time Frame: 12 months ]

The proportion of patients with PSA response according to PCWG3 criteria defined as the first occurrence of a 50% or more decline in PSA from baseline, confirmed by a second measurement at least 3 weeks later.

Current Secondary Outcome Measures (submitted: September 24, 2021)

• Objective Response Rate (ORR) [ Time Frame: Up to 53 weeks ]
  The proportion of participants who have a partial response (PR) or complete response (CR) based on RECIST 1.1 for soft tissue or PCWG3 for bone (PCWG3-modified RECIST 1.1).
• Radiographic Progression Free Survival (rPFS) [ Time Frame: Up to 53 weeks ]
  Time from randomization to the first occurrence of radiographic progression based on RECIST 1.1 for soft tissue or PCWG3-modified RECIST 1.1 for bone, respectively, or unequivocal clinical progression, or death on study from any cause.
• Overall Survival (OS) [ Time Frame: Up to 5 years ]
  Overall Survival is defined as time from randomization to death from any cause.
• PSA Progression [ Time Frame: Up to 53 weeks ]
  Time from randomization to the date of the first PSA increase from baseline ≥ 25 percent and ≥ 2 ng/ml above nadir confirmed by a second PSA assessment defining progression ≥ 3 weeks later per PCWG3.
• Duration Of Response [ Time Frame: Up to 53 weeks ]
  Time from the first date of complete response (CR) or partial response (PR) to the first occurrence of radiographic progression based on PCWG3-modified RECIST 1.1, or unequivocal clinical progression.
• Time To Initiation Of Next Treatment For Prostate Cancer [ Time Frame: Up to 5 years ]
  Time from randomization to initiation of any new treatment for prostate cancer.
• Incidences Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events As Assessed by CTCAE v5.0 (Safety Outcome Measure) [ Time Frame: After first administration of study drug to visit week 53 ]
  TEAEs will be summarized by SOC and PT using the frequency and percentage of participants experiencing any adverse event, experiencing each SOC and experiencing each PT within each SOC.
• Adverse Events Resulting In Discontinuation Of Study Drug (Safety Outcome Measure) [ Time Frame: After first administration of study drug to visit week 53 ]
  A high-level summary of TEAEs will be presented for participants who had at least one TEAE overall, seriousness, and leading to discontinuation of treatment.
• Physical Examination Findings (Safety Outcome Measure) [ Time Frame: At baseline and weeks 9, 17, 25, and 53 ]
  Percentage of patients with clinically significant abnormal changes on physical examination at weeks 9, 17, 25 and 53 will be presented by treatment group. Clinically significant abnormal physical examination findings will be captured in medical history if prior to study drug treatment.
• Changes In Blood Pressure (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]
  Percentage of patients with abnormal clinically significant changes in systolic and diastolic blood pressure will be presented by treatment group and visit.
• Changes In Heart Rate (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]
  Percentage of patients with abnormal clinically significant changes in heart rate will be presented by treatment group and visit.
• Changes In Temperature (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]
  Percentage of patients with abnormal clinically significant changes in body temperature will be presented by treatment group and visit.
• Shift From Baseline In Selected Clinical Chemistry Laboratory Values At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]
  Percentage of patients with clinically significant abnormal values of potassium, sodium, magnesium, calcium (corrected) - per CTCAE5, urea and total protein - per investigator assessment will be presented by treatment group.
• Shift From Baseline In Selected Hematology Laboratory Values At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline to week 53 ]
  Percentage of patients with clinically significant abnormal changes in hemoglobin, erythrocytes, thrombocytes, leukocytes, absolute neutrophil count, basophils, eosinophils and monocytes will be presented by treatment group.
• Changes From Baseline In Overall Electrocardiogram (ECG) Assessment At Follow-up (Safety Outcome Measure) [ Time Frame: Baseline and weeks 1, 9, 17, 25, 53 (131-I-1095 + enzalutamide treatment group); Baseline and week 53 (enzalutamide treatment group) ]
  Percentage of patients with abnormal clinically significant changes on electrocardiogram (ECG) per central reviewer's assessment will be presented by treatment group.
• Summary Of Concomitant Medications (Safety Outcome Measure) [ Time Frame: Baseline to week 53 (concomitant medications); from week 54 up to 5 years (anti-cancer therapies only) ]
  Medications will be summarized by ATC4 class and generic term using number of participants and percentages by treatment group and overall.

Original Secondary Outcome Measures (submitted: May 6, 2019)

• Objective response rate (ORR) [ Time Frame: 12 months ]
  The proportion of patients with complete or partial response based on RECIST 1.1 for soft tissue or PCWG3-modified RECIST 1.1 for bone.
• Progression free survival (PFS) [ Time Frame: 24 months ]
  Time from randomization to the first occurrence of radiographic progression, unequivocal clinical progression, or death from any cause.
• Time to initiation of next treatment for prostate cancer [ Time Frame: 24 months ]
  Time from randomization to initiation of any new treatment for prostate cancer.
• Overall survival (OS) [ Time Frame: 24 months ]
  Time from randomization to death from any cause.
• Safety and tolerability of I-131-1095 in combination with enzalutamide: CTCAE v5.0 [ Time Frame: 24 months ]
  Percentage of patients with treatment-emergent adverse events based on incidence of treatment-emergent adverse events and serious adverse events measured by CTCAE v5.0.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
• Official Title: A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone

Brief Summary

This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with prostate-specific membrane antigen (PSMA)-avid metastatic castration resistant prostate cancer (mCRPC) who have progressed on abiraterone. Participants must be chemotherapy-naive and must be ineligible or refuse to receive taxane-based chemotherapy at time of study entry. PSMA-avidity will be determined by central imaging review based on assessment of 18F-DCFPyL PET/CT imaging during screening. Eligible participants meeting the PSMA-avidity criteria will be randomized in a 2:1 ratio to receive either I-131-1095 in combination with enzalutamide (80 participants) or enzalutamide alone (40 participants). An interim analysis for efficacy will be performed after a minimum of 48 evaluable participants have PSA data for at least three months following the first dose of randomized treatment.

All participants will be followed for efficacy, safety assessments, survival status, adverse events of special interest, and new anti-cancer therapy for at least one year or to the end of the study (whichever is later) following the first dose of randomized treatment. Safety data will be monitored by an independent Data Monitoring Committee and the sponsor.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The study population includes patients with PSMA-avid mCRPC whose disease has progressed despite abiraterone therapy, and are planned for treatment with enzalutamide.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• Metastatic Prostate Cancer
• Castration-resistant Prostate Cancer
• Prostatic Neoplasm
• Cancer of the Prostate
• Progressive mCRPC

Intervention

• Drug: I-131-1095
  I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
• Drug: Enzalutamide
  Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
  Other Name: Xtandi

Study Arms

• Active Comparator: Enzalutamide
  Intervention: Drug: Enzalutamide
• Experimental: I-131-1095 in combination with enzalutamide
  Interventions:

  • Drug: I-131-1095
  • Drug: Enzalutamide

Publications *

• Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, Debus N, Holland-Letz T, Babich J, Kratochwil C. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):950-959. doi: 10.1007/s00259-017-3665-9. Epub 2017 Mar 9.
• Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: September 24, 2021): 120
• Original Estimated Enrollment (submitted: May 6, 2019): 175
• Estimated Study Completion Date: June 2024
• Estimated Primary Completion Date: June 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Male ≥ 18 years of age
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features at initial diagnosis
3. Castration-resistant prostate cancer, with serum testosterone ≤ 50 ng/dL at Screening
4. Radiographic evidence of metastatic disease prior to Randomization or up to 21 days prior to Screening

5. Disease progression on prior abiraterone therapy as defined by meeting at least one of the following criteria per the investigator:

   1. PSA progression as defined by a minimum of two rising PSA levels at least 1 week apart
   2. Soft tissue disease progression defined by RECIST 1.1
   3. Bone disease progression defined by two or more new lesions on bone scan
6. Planned to receive treatment with enzalutamide

7. Subjects who are ineligible or choose not to receive taxane-based chemotherapy based on personal preference or physician opinion. Examples of conditions that could make a patient ineligible or refuse to receive taxane-based chemotherapy, but would allow them to still be eligible to receive I-131-1095 include the following:

   1. Poor performance status
   2. Prior intolerance to cytotoxic agents
   3. History of another malignancy suspected for recurrence or metastases
   4. Other serious medical conditions such as symptomatic peripheral neuropathy CTCAE Grade 2 or higher; or clinically significant cardiovascular disease per the Investigator or treating physician
8. Subjects receiving bisphosphonate therapy must have been on stable doses for at least 4 weeks prior to Randomization
9. ECOG performance status 0-2
10. If sexually active, agree to use a medically acceptable method of birth control or sexual abstinence from the time of dosing through 28 days after the last dose of I-131-1095. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
11. Estimated life expectancy of at least 6 months as determined by the Investigator.
12. Able and willing to provide signed informed consent and comply with protocol requirements

Exclusion Criteria:

1. Received any anti-tumor therapy within 4 weeks of Randomization, with the exception of abiraterone, GnRH therapy and non-radioactive bone-targeted agents
2. Received prior chemotherapy for castration-resistant prostate cancer
3. Superscan as evidenced on baseline bone scan
4. Treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 within 6 months prior to Randomization
5. Prior hemi-body irradiation
6. Prior PSMA-targeted radioligand therapy
7. Major surgery within 4 weeks of Randomization

8. Impaired organ function as evidenced by the following laboratory values at Screening:

   1. Absolute neutrophil count < 1500 μL
   2. Platelet count < 100,000/μL
   3. Hemoglobin < 9.5 g/dL
   4. Albumin < 3.0 g/dL (30 g/L)
   5. Total bilirubin > 2 x ULN unless in instances of known or suspected Gilbert's disease
   6. AST or ALT > 2.5 x ULN
   7. Calculated creatinine clearance (CrCL) < 30 mL/min (Cockroft-Gault equation), or currently on renal dialysis.
9. QT interval corrected for heart rate (QTc) > 470 msec
10. Previous use of enzalutamide for more than 7 days prior to consent
11. Planned initiation of alternative therapy for prostate cancer, investigational therapy, or participation in clinical trials during the study
12. History or risk of seizure (i.e., clinically significant neurological disorder) or any other condition that contraindicates treatment with enzalutamide
13. Gastrointestinal disorder affecting absorption of oral medications
14. Known or suspected brain metastasis or active leptomeningeal disease
15. Active malignancy other than prostate cancer, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or non-muscle invasive bladder/urothelial cancer
16. Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completing the study.

Sex/Gender

• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Only male subjects will be enrolled in this study.

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, United States

Administrative Information

• NCT Number: NCT03939689
• Other Study ID Numbers: 1095-2301
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Progenics Pharmaceuticals, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Progenics Pharmaceuticals, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Jean-Claude Provost, MD; Progenics Pharmaceuticals, Inc.

• PRS Account: Progenics Pharmaceuticals, Inc.
• Verification Date: August 2022